Melanoma vaccine reduces death or cancer recurrence by 42%

The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.